✦ LIBER ✦

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

✍ Scribed by Nam H. Dang; Luis Fayad; Peter McLaughlin; Jorge E. Romaguara; Fredrick Hagemeister; Andre Goy; Sattva Neelapu; Felipe Samaniego; Pamela L. Walker; Michael Wang; Maria A. Rodriguez; Ann T. Tong; Barbara Pro

Book ID: 108675312
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 447 KB
Volume: 138
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2007.06684.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of denileukin diftitox fo

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma

✍ Nam H. Dang; Barbara Pro; Fredrick B. Hagemeister; Felipe Samaniego; Dan Jones; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 507 KB

Phase II study of oral fludarabine in co

Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma

✍ Kensei Tobinai; Ken-ichi Ishizawa; Michinori Ogura; Kuniaki Itoh; Yasuo Morishim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 955 KB

Phase I trial of fludarabine, bortezomib

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

✍ Paul M. Barr; Pingfu Fu; Hillard M. Lazarus; Nancy Horvath; Stanton L. Gerson; O 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Multicenter phase II study of bendamusti

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

✍ Ken Ohmachi; Kiyoshi Ando; Michinori Ogura; Toshiki Uchida; Kuniaki Itoh; Nobuko 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

Feasibility and pharmacokinetic study of

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin’s lymphoma

✍ Michinori Ogura; Kiyoshi Ando; Masafumi Taniwaki; Takashi Watanabe; Toshiki Uchi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Rituximab monotherapy with eight weekly

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

✍ Kensei Tobinai; Tadahiko Igarashi; Kuniaki Itoh; Mitsutoshi Kurosawa; Hirokazu N 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB